Key to robust biomarkers and systems medicine?

Perhaps no two areas hold greater promise for the massive challenges of healthcare than Biomarkers for precision medicine and Systems biology for personalised patient care.  Although obscured by high market fragmentation, each of these solutions ultimately spans the vast landscape from drug discovery and development, to safety testing and clinical trials, to clinical practice.  The perspective of predictive tox and safety allows these lifecycles to be viewed more fully, and shows how  in vitro and in silico tools work together as mechanistic and predictive complements.

Drug Discovery World                                          by Robert G. Hunter

Read article here

Better results, less side effects